3970-66-9

Basic information

• Product Name: 1-BENZYL-4-METHYLPIPERIDIN-4-OL
• Synonyms: 1-BENZYL-4-METHYLPIPERIDIN-4-OL;1-Benzyl-4-hydroxy-4-methylpiperidine;1-Benzyl-4-methyl-4-piperidinol
• CAS NO: 3970-66-9
• Molecular Formula: C₁₃H₁₉NO
• Molecular Weight: 205.29606
• Mol File: 3970-66-9.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BENZYL-4-METHYLPIPERIDIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-4-METHYLPIPERIDIN-4-OL(3970-66-9)
• EPA Substance Registry System: 1-BENZYL-4-METHYLPIPERIDIN-4-OL(3970-66-9)

Safety Data

• Hazardous Substances Data: 3970-66-9(Hazardous Substances Data)

Usage

General Description

1-BENZYL-4-METHYLPIPERIDIN-4-OL is a chemical compound that belongs to the class of benzylpiperidine opioids. It is a synthetic opioid analgesic with potent pain-relieving properties and is commonly used in the treatment of severe pain. The compound acts on the central nervous system to produce its analgesic effects by binding to and activating opioid receptors. However, it also has the potential for abuse and addiction, and its use is strictly controlled. Additionally, 1-BENZYL-4-METHYLPIPERIDIN-4-OL may cause side effects such as drowsiness, respiratory depression, and constipation, and should only be used under the supervision of a healthcare professional.

Upstream product

• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 75-16-1 methylmagnesium bromide 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 710978-27-1 1-benzyl-4-isopropylcarboxamido-4-methylpiperidine 
• 3970-68-1 4-methylpiperidin-4-ol 
• 1186220-76-7 4-amino-N-(1-(3-(4-[¹⁸F]fluorophenoxy)propyl)-4-methylpiperidin-4-yl)-2-methoxybenzamide 
• 1186220-75-6 tert-butyl 4-(1-(3-(4-[¹⁸F]fluorophenoxy)propyl)-4-methylpiperidin-4-ylcarbamoyl)-3-methoxyphenylcarbamate 
• 155928-28-2 4-amino-N-[1-(3-(4-fluorophenoxy)propyl)-4-methylpiperidin-4-yl]-2-methoxy-benzamide 
• 1186220-74-5 tert-butyl 4-(1-(3-(4-fluorophenoxy)propyl)-4-methylpiperidin-4-ylcarbamoyl)-3-methoxyphenylcarbamate 
• 1186220-73-4 tert-butyl 3-methoxy-4-(4-methylpiperidin-4-ylcarbamoyl)phenylcarbamate 
• 1186220-72-3 tert-butyl 4-(1-benzyl-4-methylpiperidin-4-ylcarbamoyl)-3-methoxyphenylcarbamate 
• 32018-56-7 1-benzyl-4-methyl-1 ,2,3,6-tetrahydropyridine 
• 1093064-92-6 C₁₈H₂₀ClN₃O 
• 1093063-93-4 C₂₃H₂₅N₃ 
• 1093063-94-5 C₁₆H₁₉N₃ 
• 1067188-65-1 tert-butyl 4-methyl-4-(5-methyl-2-nitrophenylamino)piperidine-1-carboxylate 
• 1067188-66-2 tert-butyl 4-(2-amino-5-methylphenylamino)-4-methylpiperidine-1-carboxylate 

Relevant articles and documents

Deoxygenative Borylation of Secondary and Tertiary Alcohols

Two different approaches for the deoxygenative radical borylation of secondary and tertiary alcohols are presented. These transformations either proceed through a metal-free silyl-radical-mediated pathway or utilize visible-light photoredox catalysis. Readily available xanthates or methyl oxalates are used as radical precursors. The reactions show broad substrate scope and high functional-group tolerance, and are conducted under mild and practical conditions.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.